Revvity and Element Biosciences Collaborate for Newborn IVD Solutions
WALTHAM, Mass. & SAN DIEGO — Revvity, Inc. (NYSE: RVTY), a leader in health science solutions, and Element Biosciences, Inc., an innovator in DNA sequencing, have announced a strategic partnership to enhance in vitro diagnostic (IVD) solutions specifically for neonatal sequencing. This collaboration aims to pioneer advances in newborn health through cutting-edge genomic technology.
Strategic Partnership Overview
The partnership between Revvity and Element focuses on co-developing a comprehensive IVD workflow tailored for neonatal needs. It will provide customers access to a research use only (RUO) version of the newborn sequencing research workflow. This initiative builds on Revvity's previous work in automated next-generation sequencing (NGS) workflows for newborn sequencing research, further solidifying Element's progress toward the regulatory approval of its benchtop AVITI™ sequencing system.
Advancements in Newborn Health
Yves Dubaquie, the senior vice president of diagnostics at Revvity, expressed the company's commitment, stating that this collaboration marks a crucial stride in advancing newborn health through innovative technological solutions. By merging Revvity's expertise in newborn screening and rare disease detection with Element’s advanced capabilities, they aim to provide a highly efficient and accessible solution for neonatal sequencing in both clinical and research settings.
Benefits of the New IVD Solution
The new IVD solution being developed is expected to significantly enhance the capabilities of both companies. It will expand the reach of Element's AVITI sequencing system while integrating Revvity’s newborn sequencing research tools, which include essential devices like sample collection tools, dried blood spot punchers, automated nucleic acid extractors, and comprehensive software for data analysis and interpretation. Together, they will form an end-to-end solution to facilitate groundbreaking neonatal research and support regulatory processes for advanced IVD solutions.
Global Impact on Newborn Screening Programs
Yaron Hakak, senior vice president of corporate and business development at Element, added that this collaboration is designed to meet the specific requirements of newborn screening programs worldwide, ensuring that the offering is of high quality and comprehensive. The aim is to pursue regulatory approval for the AVITI system, paving the way for new diagnostic solutions to emerge from this partnership and other market-leading collaborators.
About Revvity
Revvity operates at the forefront of healthcare innovation, enabling transformative solutions from discovery to diagnosis and treatment. They focus on delivering health science technologies, services, and workflows that encompass a wide array of areas, including multi-omics technologies, diagnostic screening, and patient care. Revvity had a substantial revenue exceeding $2.7 billion in 2023, employing over 11,000 professionals. The company is part of the S&P 500 index and serves a global clientele across pharmaceuticals, diagnostics, academia, and government sectors.
About Element Biosciences, Inc.
Element Biosciences stands as a pioneering force in the life sciences sector, aiming to democratize access to advanced biological tools that encourage impactful discoveries. Their commitment to developing revolutionary DNA sequencing technologies propels their mission to deliver affordable and high-quality data to researchers, enhancing the quest for scientific advancements.
Frequently Asked Questions
What is the purpose of the collaboration between Revvity and Element Biosciences?
The collaboration aims to develop a comprehensive IVD workflow solution for neonatal sequencing to enhance newborn health through advanced genomic technologies.
What innovative technologies are being integrated in this partnership?
The partnership integrates Revvity’s sequencing research tools and Element's AVITI sequencing system, offering a robust, end-to-end solution for neonatal research and diagnostics.
Who benefits from the new IVD solution?
The IVD solution will benefit newborn screening programs by providing a high-quality, comprehensive offering tailored to their unique needs.
What are Revvity's main areas of focus?
Revvity focuses on health science solutions ranging from translational multi-omics technologies to screening, detection, and diagnosis in healthcare.
How large is Revvity as a company?
Revvity has more than 11,000 employees and generated over $2.7 billion in revenue in 2023, serving customers in over 190 countries.
